{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:32:09Z","timestamp":1791340329771,"version":"4.3.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2001,7,1]],"date-time":"2001-07-01T00:00:00Z","timestamp":993945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2001,7,1]],"date-time":"2001-07-01T00:00:00Z","timestamp":993945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2001,7]]},"DOI":"10.1136\/ard.60.7.660","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T10:45:32Z","timestamp":1027766732000},"page":"660-669","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"title":["Effects of treatment with a fully human anti-tumour necrosis factor \u03b1 monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNF\u03b1 in patients with rheumatoid arthritis"],"prefix":"10.1016","volume":"60","author":[{"given":"P","family":"Barrera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L A B","family":"Joosten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A A","family":"den Broeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L B A","family":"van de Putte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P L C M","family":"van Riel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W B","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.60.7.660_bib1","doi-asserted-by":"crossref","first-page":"I96","DOI":"10.1136\/ard.58.2008.i96","article-title":"Treatment of rheumatoid arthritis with interleukin 1 receptor antagonist.","volume":"58(suppl I)","author":"Bresnihan","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.60.7.660_bib2","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha momoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.60.7.660_bib3","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","article-title":"Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"key":"10.1136\/ard.60.7.660_bib4","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/rheumatology\/34.4.334","article-title":"The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis.","volume":"34","author":"Rankin","year":"1995","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.60.7.660_bib5","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease.","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.60.7.660_bib6","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(97)80083-9","article-title":"Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease.","volume":"349","author":"Stack","year":"1997","journal-title":"Lancet"},{"key":"10.1136\/ard.60.7.660_bib7","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis.","volume":"130","author":"Moreland","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.60.7.660_bib8","first-page":"S81","article-title":"30 months of treatment with a TNF\u03b1 receptor-fusion protein (TNFR55-IGG1, RO 45\u20132081) in patients with severe refractory RA [abstract].","volume":"40","author":"Sander","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.60.7.660_bib9","first-page":"S57","article-title":"Generation of fully human anti-TNF antibody D2E7 [abstract].","volume":"41","author":"Salfeld","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.60.7.660_bib10","first-page":"S55","article-title":"Long term efficacy and tolerability of multiple i.v. doses of the fully human anti-TNF antibody D2E7 in patients with rheumatoid arthritis [abstract].","volume":"41","author":"Rau","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.60.7.660_bib11","first-page":"S57","article-title":"A single dose placebo controlled phase I study of the fully human anti-TNF antibody D2E7 in patients with rheumatoid arthritis [abstract].","volume":"41","author":"van de Putte","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.60.7.660_bib12","first-page":"S400","article-title":"Efficacy of the fully human anti TNF antibody D2E7 in rheumatoid arthritis [abstract].","volume":"42","author":"van de Putte","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.60.7.660_bib13","doi-asserted-by":"crossref","first-page":"I70","DOI":"10.1136\/ard.58.2008.i70","article-title":"Preliminary results of early clinical trials with the fully human anti-TNF\u03b1 monoclonal antibody D2E7.","volume":"58 (suppl I)","author":"Kempeni","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.60.7.660_bib14","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/art.1780390702","article-title":"Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis.","volume":"39","author":"Tak","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.60.7.660_bib15","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.4049\/jimmunol.156.4.1646","article-title":"In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects.","volume":"156","author":"Lorenz","year":"1996","journal-title":"J Immunol"},{"key":"10.1136\/ard.60.7.660_bib16","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/1529-0131(199807)41:7<1258::AID-ART17>3.0.CO;2-1","article-title":"Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis.","volume":"41","author":"Paleolog","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.60.7.660_bib17","first-page":"297","article-title":"Anti-tumor necrosis factor alpha therapy of rheumatoid arthritis. Mechanism of action.","volume":"8","author":"Feldmann","year":"1997","journal-title":"Eur Cytokine Netw"},{"key":"10.1136\/ard.60.7.660_bib18","first-page":"225","article-title":"Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist.","volume":"6","author":"Butler","year":"1995","journal-title":"Eur Cytokine Netw"},{"key":"10.1136\/ard.60.7.660_bib19","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1002\/1529-0131(200011)43:11<2391::AID-ANR3>3.0.CO;2-F","article-title":"Systemic anti-tumour necrosis factor alpha therapy in rheumatoid arthritis (RA) down-regulates synovial tumour necrosis factor alpha synthesis.","volume":"43","author":"Ulfgren","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.60.7.660_bib20","first-page":"S197","article-title":"Reduced cellularity and expression of adhesion molecules and cytokines after treatment with soluble human recombinant TNF receptor (p75) in RA patients [abstract].","volume":"42","author":"Verschueren","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.60.7.660_bib21","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.60.7.660_bib22","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/ard.49.11.916","article-title":"Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score.","volume":"49","author":"van der Heijde","year":"1990","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.60.7.660_bib23","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1046\/j.1365-2567.1997.00285.x","article-title":"The effects of dexamethasone and chlorpromazine on tumour necrosis factor-alpha, interleukin-1 beta, interleukin-1 receptor antagonist and interleukin-10 in human volunteers.","volume":"91","author":"Bleeker","year":"1997","journal-title":"Immunology"},{"key":"10.1136\/ard.60.7.660_bib24","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/art.1780360807","article-title":"Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy.","volume":"36","author":"Barrera","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.60.7.660_bib25","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1006\/cyto.1996.0098","article-title":"A semi-quantitative reverse transcriptase polymerase chain reaction method for measurement of mRNA for TNF-alpha and IL-1 beta in whole blood cultures: its application in typhoid fever and exentric exercise.","volume":"8","author":"Netea","year":"1996","journal-title":"Cytokine"},{"key":"10.1136\/ard.60.7.660_bib26","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.1780400807","article-title":"Effects of pulse methylprednisolone on inflammatory mediators in peripheral blood, synovial fluid, and synovial membrane in rheumatoid arthritis.","volume":"40","author":"Youssef","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.60.7.660_bib27","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1002\/1529-0131(200009)43:9<1951::AID-ANR5>3.0.CO;2-K","article-title":"Synovial macrophage depletion with clodronate liposomes in rheumatoid arthritis.","volume":"43","author":"Barrera","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.60.7.660_bib28","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/art.1780390105","volume":"39","author":"van Gestel","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.60.7.660_bib29","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1086\/517824","article-title":"Posttranscriptional down-regulation of tumor necrosis factor-alpha and interleukin-1beta production in acute meningococcal infections.","volume":"177","author":"van Deuren","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1136\/ard.60.7.660_bib30","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1182\/blood.V87.6.2095.bloodjournal8762095","article-title":"Biologic basis for interleukin-1 in disease.","volume":"87","author":"Dinarello","year":"1996","journal-title":"Blood"},{"key":"10.1136\/ard.60.7.660_bib31","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1002\/1529-0131(199812)41:12<2205::AID-ART16>3.0.CO;2-Q","article-title":"Reduction of NOS2 overexpression in rheumatoid arthritis patients treated with anti-tumor necrosis factor alpha monoclonal antibody (cA2).","volume":"41","author":"Perkins","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.60.7.660_bib32","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/art.1780400408","article-title":"Elevated cytokine messenger RNA levels in the peripheral blood of patients with rheumatoid arthritis suggest different degrees of myeloid cell activation.","volume":"40","author":"Schulze Koops","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.60.7.660_bib33","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/ard.58.10.648","article-title":"Superinduction of IL-8 mRNA in activated monocyte-derived macrophages from rheumatoid arthritis patients.","volume":"58","author":"Rodenburg","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.60.7.660_bib34","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0140-6736(89)90430-3","article-title":"Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis.","volume":"2","author":"Brennan","year":"1989","journal-title":"Lancet"},{"key":"10.1136\/ard.60.7.660_bib35","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/1529-0131(199806)41:6<1083::AID-ART15>3.0.CO;2-9","article-title":"Elevated levels of soluble interleukin-1 receptor type II and interleukin-1 receptor antagonist in patients with chronic arthritis: correlations with markers of inflammation and joint destruction.","volume":"41","author":"Jouvenne","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.60.7.660_bib36","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/rheumatology\/36.9.950","article-title":"Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumour necrosis factor alpha blockade.","volume":"36","author":"Davis","year":"1997","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.60.7.660_bib37","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/art.1780390703","article-title":"Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis.","volume":"39","author":"Paleolog","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.60.7.660_bib38","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/art.1780380204","article-title":"Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen- and zymosan-induced arthritis.","volume":"38","author":"van de Loo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.60.7.660_bib39","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1006\/cyto.1998.0372","article-title":"Different roles of tumour necrosis factor alpha and interleukin 1 in murine streptococcal cell wall arthritis.","volume":"10","author":"Kuiper","year":"1998","journal-title":"Cytokine"},{"key":"10.1136\/ard.60.7.660_bib40","doi-asserted-by":"crossref","first-page":"I40","DOI":"10.1136\/ard.58.2008.i40","article-title":"Role of tumour necrosis factor \u03b1 in experimental arthritis: separate activity of interelukin 1\u03b2 in chronicity and cartilage destruction.","volume":"58(suppl I)","author":"van den Berg","year":"1999","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724442015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724442015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.60.7.660","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T05:34:10Z","timestamp":1737264850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724442015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,7]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2001,7]]}},"alternative-id":["S0003496724442015"],"URL":"https:\/\/doi.org\/10.1136\/ard.60.7.660","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2001,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of treatment with a fully human anti-tumour necrosis factor \u03b1 monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNF\u03b1 in patients with rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.60.7.660","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2001 Annals of the Rheumatic Diseases. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}